As AI accelerates target discovery and pushes more candidates toward the bench, assay development and transfer have become critical bottlenecks. Teams relying on one-factor-at-a-time (OFAT) workflows ...
Recently, a pharmaceutical company came to the antibody-discovery specialist, Abveris, with a serious problem. The pharmaceutical company had tried and failed to develop a monoclonal antibody for an ...
Molecular characteristics of BRAF mutated non-small cell lung cancer and therapeutic outcomes: Multi-institution study. This is an ASCO Meeting Abstract from the 2021 ASCO Annual Meeting I. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results